2023
Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics
Altibi A, Alani A, Zhao Y, Masri A. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics. Current Cardiology Reports 2023, 25: 583-595. PMID: 37103749, DOI: 10.1007/s11886-023-01883-w.Peer-Reviewed Original ResearchConceptsCardiac myosin inhibitorCardiac magnetic resonance imagingHypertrophic cardiomyopathyCare of patientsClinical trialsPathophysiology of hypertrophic cardiomyopathyCardiac magnetic resonanceNew drug therapiesHypertrophic cardiomyopathy diagnosisActin-myosin cross-bridgesLongitudinal imagingMagnetic resonance imagingMyosin inhibitorTherapeutic optionsAbstract PurposeDrug therapyOral moleculesLongitudinal imaging modalityCardiomyopathyPatientsMonitoring patientsImaging modalitiesResonance imagingInvestigate new drug therapiesSarcomere level
2022
Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy
Al’Aref S, Altibi A, Malkawi A, Mansour M, Baskaran L, Masri A, Rahmouni H, Abete R, Andreini D, Aquaro G, Barison A, Bogaert J, Camastra G, Carigi S, Carrabba N, Casavecchia G, Censi S, Cicala G, Conte E, De Cecco C, De Lazzari M, Di Giovine G, Di Roma M, Dobrovie M, Focardi M, Gaibazzi N, Gismondi A, Gravina M, Guglielmo M, Lanzillo C, Lombardi M, Lorenzoni V, Lozano-Torres J, Margonato D, Martini C, Marzo F, Masci P, Masi A, Memeo R, Moro C, Mushtaq S, Nese A, Palumbo A, Pavon A, Pedrotti P, Pepi M, Marra M, Pica S, Pradella S, Presicci C, Rabbat M, Raineri C, Rodriguez-Palomares J, Sbarbati S, Schoepf U, Squeri A, Sverzellati N, Symons R, Tat E, Timpani M, Todiere G, Valentini A, Varga-Szemes A, Volpe A, Fusini L, Guaricci A, Schwitter J, Pontone G. Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy. European Heart Journal - Cardiovascular Imaging 2022, 24: 472-482. PMID: 35792682, PMCID: PMC10029842, DOI: 10.1093/ehjci/jeac124.Peer-Reviewed Original ResearchConceptsRight ventricular systolic dysfunctionCardiac magnetic resonanceAll-cause mortalityPredictor of all-cause mortalityRV ejection fractionPrognostic valueEjection fractionSystolic dysfunctionHeart failureQuantitative assessment of RV functionMean left ventricular ejection fractionAssessment of RV functionBaseline cardiac magnetic resonanceRV systolic dysfunctionRV systolic functionMedian follow-upNormal renal functionVentricular systolic dysfunctionVentricular ejection fractionReduced ejection fractionKaplan-Meier curvesRV functionNYHA III/IVSystolic functionRenal dysfunction
2020
Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis
Barssoum K, Altibi A, Rai D, Kumar A, Kharsa A, Chowdhury M, Thakkar S, Shahid S, Abdelazeem M, Abuzaid A, Baibhav B, Parikh V, Feitell S, Balmer‐Swain M, Rao M, Amsallem M, Nanda N. Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis. Echocardiography 2020, 37: 2061-2070. PMID: 33058271, DOI: 10.1111/echo.14886.Peer-Reviewed Original ResearchConceptsLeft ventricular global longitudinal strainGlobal circumferential strainSpeckle tracking echocardiographyStandardized mean differenceCardiac sarcoidosisCardiac magnetic resonanceSarcoidosis groupTracking echocardiographyHealthy controlsConfidence intervalsExtra-cardiac sarcoidosisGlobal longitudinal strainSubclinical myocardial involvementMeta-analysisScreening of CSAdvanced imaging modalitiesRandom-effects modelEnglish-language articlesPositron emission tomographyMyocardial involvementSarcoidosis patientsCardiac symptomsFDG-PETLongitudinal strainEchocardiography